Pharmacotherapeutic Options for Weight Regain After Bariatric Surgery

Knight, Michael G.; Seetharaman, Sujatha; Dutton, Wesley P.; Chhabria, Shradha; Stanford, Fatima Cody

doi:10.1007/s11938-021-00358-7

Cited by 7 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To establish which medications should not be prescribed for the treatment of patients with obesity, experts state that the following medications are not considered anti-obesity and therefore should not be prescribed for weight loss purposes (LE: B; R: III): 18,83,88,90,115,116 • thyroid hormones;…”

Section: Non-recommended Therapiesmentioning

confidence: 99%

“…Furthermore, some drugs may impact weight loss; however, the loss is not significant; hence, they are not approved as anti-obesity medications. These include (LE: B; R: III) 18,83,90,115,116 • metformin;…”

Section: Non-recommended Therapiesmentioning

confidence: 99%

“…To establish which medications should not be prescribed for the treatment of patients with obesity, experts state that the following medications are not considered anti‐obesity and therefore should not be prescribed for weight loss purposes (LE: B; R: III): 18,83,88,90,115,116 thyroid hormones; human chorionic gonadotrophin; growth hormone; diuretics; laxatives; and drugs that have not been approved or that have been recalled. Furthermore, some drugs may impact weight loss; however, the loss is not significant; hence, they are not approved as anti‐obesity medications. These include (LE: B; R: III) 18,83,90,115,116 metformin; topiramate onotherapy; bupropion monotherapy; anxiolytics; and serotonin reuptake inhibitors. Additionally, considering that obesity is a chronic disease, the panel of experts does not recommend the use of drugs that are exclusively approved for short‐term use (LE: A; R: III).…”

Section: Consensus Statementmentioning

confidence: 99%

See 2 more Smart Citations

Consensus on pharmacological treatment of obesity in Latin America

Cappelletti,

Valenzuela Montero,

Cercato

et al. 2023

Obesity Reviews

View full text Add to dashboard Cite

SummaryA panel of 10 experts in obesity from various Latin American countries held a Zoom meeting intending to reach a consensus on the use of anti‐obesity medicines and make updated recommendations suitable for the Latin American population based on the available evidence. A questionnaire with 16 questions was developed using the Patient, Intervention, Comparison, Outcome (Result) methodology, which was iterated according to the modified Delphi methodology, and a consensus was reached with 80% or higher agreement. Failure to reach a consensus led to a second round of analysis with a rephrased question and the same rules for agreement. The recommendations were drafted based on the guidelines of the American College of Cardiology Foundation/American Heart Association Task Force on Practice. This panel of experts recommends drug therapy in patients with a body mass index of ≥30 or ≥27 kg/m2 plus at least one comorbidity, when lifestyle changes are not enough to achieve the weight loss objective; alternatively, lifestyle changes could be maintained while considering individual parameters. Algorithms for the use of long‐term medications are suggested based on drugs that increase or decrease body weight, results, contraindications, and medications that are not recommended. The authors concluded that anti‐obesity treatments should be individualized and multidisciplinary.

show abstract